Nucana Plc Stock In The News
| NCNA Stock | USD 0.80 0.01 1.23% |
Our overall analysis of NuCana PLC's news coverage and content from conventional and social sources shows investors' bearish mood towards NuCana PLC. The specific impact of NuCana PLC news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of NuCana PLC's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using NuCana PLC headlines in addition to utilizing other, more conventional financial analysis modules. Check out NuCana PLC Backtesting and NuCana PLC Hype Analysis. For information on how to trade NuCana Stock refer to our How to Trade NuCana Stock guide.
NuCana |
NuCana PLC Today Top News and Investor Outlook
NuCana PLC Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide NuCana and other traded companies coverage with news coverage. We help investors stay connected with NuCana headlines for the 14th of March 2025 to make an informed investment decision based on correlating the impacts of news items on NuCana Stock performance. Please note that trading solely based on the NuCana PLC hype is not for everyone as timely availability and quick action are needed to avoid losses.
NuCana PLC stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the NuCana earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about NuCana PLC that are available to investors today. That information is available publicly through NuCana media outlets and privately through word of mouth or via NuCana internal channels. However, regardless of the origin, that massive amount of NuCana data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NuCana PLC news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NuCana PLC relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NuCana PLC's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NuCana PLC alpha.
NuCana Largest EPS Surprises
Earnings surprises can significantly impact NuCana PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-14 | 2024-09-30 | -3.46 | -2.1898 | 1.2702 | 36 | ||
2021-05-19 | 2021-03-31 | -16.86 | -19.0 | -2.14 | 12 | ||
2021-08-19 | 2021-06-30 | -19.27 | -17.0 | 2.27 | 11 | ||
2022-11-16 | 2022-09-30 | -11.64 | -9.0 | 2.64 | 22 | ||
2023-08-16 | 2023-06-30 | -12.79 | -10.0 | 2.79 | 21 | ||
2023-11-16 | 2023-09-30 | -10.07 | -13.0 | -2.93 | 29 |
NuCana PLC Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to NuCana PLC Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
13th of March 2025
Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush at thelincolnianonline.com
12th of March 2025
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroin... at globenewswire.com
11th of March 2025
NuCana Projected to Post Earnings on Wednesday - Defense World at news.google.com
11th of March 2025
Rhumbline Advisers Has 94,000 Stock Position in Zura Bio Limited - Defense World at news.google.com
7th of March 2025
Inozyme Pharma Inc expected to post a loss of 41 cents a share - Earnings Preview - Tradin... at news.google.com
6th of March 2025
Cidara Therapeutics GAAP EPS of -5.37 misses by 1.52 at seekingalpha.com
6th of March 2025
Acquisition by Parschauer Karah Herdman of 29532 shares of Tenaya Therapeutics at 7.12 sub... at gurufocus.com
5th of March 2025
Acadia Pharmaceuticals Q4 Earnings Lag Estimates at finance.yahoo.com
5th of March 2025
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corpora... at finance.yahoo.com
5th of March 2025
Financial Analysis Eloxx Pharmaceuticals and Acumen Pharmaceuticals at thelincolnianonline.com
5th of March 2025
Day One Biopharmaceuticals, Inc. A Bull Case Theory at finance.yahoo.com
4th of March 2025
US Futures Tumble As Traders Await Trumps Congress Address Volatility Is Certainly Being F... at benzinga.com
28th of February 2025
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strate... at finance.yahoo.com
27th of February 2025
Day One Biopharmaceuticals, Inc. Q4 2024 Earnings Call Transcript at insidermonkey.com
26th of February 2025
Acadia Pharmaceuticals Q4 Earnings Lag Estimates at zacks.com
24th of February 2025
Day One Biopharmaceuticals Q4 2024 Earnings Preview at seekingalpha.com
21st of February 2025
Disposition of 2159 shares by Jason Lettmann of Alx Oncology at 1.1502 subject to Rule 16b... at news.google.com
21st of February 2025
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young... at gurufocus.com
14th of February 2025
Acquisition by Clark Ian T of 15000 shares of Corvus Pharmaceuticals at 2.49 subject to Ru... at gurufocus.com
12th of February 2025
ADAGE CAPITAL PARTNERS GP, L.L.C. Increases Stake in Mereo BioPharma Group PLC at gurufocus.com
11th of February 2025
Insider Trading at MacroaxisInsider
6th of February 2025
Disposition of 1617 shares by Randolph Sophia of Alx Oncology at 11.0704 subject to Rule 1... at MacroaxisInsider
29th of January 2025
Shareholders in CytomX Therapeutics are in the red if they invested five years ago - Yahoo... at news.google.com
29th of January 2025
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqorys TROP2 Antibody Dr... at gurufocus.com
27th of January 2025
Could Corvus Pharmaceuticals Face Challenges Ahead in Price Movement at kalkinemedia.com
24th of January 2025
Down -35.58 percent in 4 Weeks, Heres Why You Should You Buy the Dip in Zura Bio Limited at zacks.com
21st of January 2025
Disposition of 3219 shares by Siemers Eric of Acumen Pharmaceuticals at 1.59 subject to Ru... at MacroaxisInsider
17th of January 2025
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN at news.google.com
16th of January 2025
Heres Why Cidara Therapeutics, Inc. Is Skyrocketing - MSN at news.google.com
15th of January 2025
Acquisition by Adam Dubow of 59000 shares of Day One subject to Rule 16b-3 at MacroaxisInsider
13th of January 2025
Were Not Worried About Corvus Pharmaceuticals Cash Burn at simplywall.st
10th of January 2025
NuCana Shares Down 6.5 percent Whats Next at thelincolnianonline.com
7th of January 2025
Acquisition by Oconnell Daniel Joseph of 338000 shares of Acumen Pharmaceuticals at 1.83 s... at news.google.com
18th of December 2024
ZyVersa Therapeutics CEO, Stephen C. Glover, to Attend JPMs Healthcare Conference 2025 in ... at finance.yahoo.com
18th of December 2024
Corvus stock falls after eczema trial data at seekingalpha.com
18th of December 2024
Mereo BioPharma Group Shares Down 4.5 percent Heres What Happened at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NuCana PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NuCana PLC's short interest history, or implied volatility extrapolated from NuCana PLC options trading.
Check out NuCana PLC Backtesting and NuCana PLC Hype Analysis. For information on how to trade NuCana Stock refer to our How to Trade NuCana Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NuCana PLC. If investors know NuCana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NuCana PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NuCana PLC is measured differently than its book value, which is the value of NuCana that is recorded on the company's balance sheet. Investors also form their own opinion of NuCana PLC's value that differs from its market value or its book value, called intrinsic value, which is NuCana PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NuCana PLC's market value can be influenced by many factors that don't directly affect NuCana PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NuCana PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if NuCana PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NuCana PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.